EEF1A2 identified as a hub gene associated with the severity of metabolic dysfunction-associated steatotic liver disease

Jian Zhang; Huiwen Wang; Qianbing Wang; Juan Mo; Lei Fu; Shifang Peng

doi:10.1007/s00335-024-10078-9

EEF1A2 identified as a hub gene associated with the severity of metabolic dysfunction-associated steatotic liver disease

Mamm Genome. 2024 Oct 16. doi: 10.1007/s00335-024-10078-9. Online ahead of print.

Authors

Jian Zhang¹, Huiwen Wang², Qianbing Wang¹, Juan Mo¹, Lei Fu³, Shifang Peng⁴

Affiliations

¹ Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Infection Control Center of Xiangya Hospital, Central South University, Changsha, Hunan, China.
³ Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China. fulei92@126.com.
⁴ Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China. sfp1988@csu.edu.cn.

PMID: 39414652
DOI: 10.1007/s00335-024-10078-9

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease that ranges from metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH), and may eventually progress to cirrhosis and hepatocellular carcinoma (HCC). The underlying mechanism of MASLD remains incompletely understood. This study aimed to identify key gene implicated in MASLD pathogenesis and validate its correlation with disease severity through an integration of bioinformatics and experimental approaches. Liver transcriptome data from MASLD patients were obtained from the Gene Expression Omnibus (GEO) database. A diet-induced MASLD mouse model was developed, and liver RNA-sequencing was performed. Liver specimens and clinical data from patients were collected for further analysis. A total of 120 differentially expressed genes (DEGs) were shared between datasets GSE89632 and GSE213621, with functional enrichment in inflammatory, metabolic, and cell cycle-related pathways. Protein-protein interaction (PPI) network analysis identified three modules associated with MASLD, with the cell cycle-related module being the most notable. EEF1A2 was identified as a novel hub gene and revealed to be elevated with MASLD progression through dataset analysis. EEF1A2 was confirmed to be highly expressed in the livers of both MASLD mouse models and patients. Moreover, the increased expression of EEF1A2 in MASH was positively correlated with higher serum alanine aminotransferase (ALT), alanine aminotransferase (AST), total cholesterol (TC), and body mass index (BMI). In conclusion, EEF1A2 is a novel hub gene significantly associated with MASLD severity and is a promising biomarker and therapeutic target for MASLD.

Keywords: Biomarker; EEF1A2; Integrated bioinformatics; Metabolic dysfunction-associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease; Prognosis.

Abstract

Grants and funding